SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
NUCRYST Pharmaceuticals Corp. Announces Management Realignment and R&D Portfolio Change; Discontinued Development of NPI 32101 for Inflammatory Bowel Disease (IBD)